Form 4: Fulgent Genetics CEO Ming Hsieh Reports Stock Withholding
Statement of Changes in Beneficial Ownership
CEO Ming Hsieh reported the withholding of 2,949 shares of Fulgent Genetics common stock to satisfy tax obligations related to restricted stock unit vesting.
Summary
- Ming Hsieh, CEO and 10% owner of Fulgent Genetics, Inc., executed a transaction on May 26, 2026.
- 2,949 shares of common stock were withheld by the company at a price of $17.67 per share.
- The transaction was conducted to satisfy tax withholding obligations arising from the vesting of restricted stock units granted on February 26, 2024.
- Following this transaction, Mr. Hsieh maintains direct ownership of 897,685 shares and indirect ownership of 8,117,931 shares through various trusts and family accounts.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event, as it represents a routine administrative tax transaction by an insider.
Positives
- The transaction is a routine administrative action related to tax obligations rather than a discretionary sale of shares.
- The CEO maintains a significant equity stake in the company, signaling continued alignment with shareholder interests.
Negatives
- The transaction results in a minor reduction in the CEO's direct share count.
Risks
- Concentration of ownership in trusts and family accounts may influence corporate governance decisions.
Future Outlook
No forward-looking guidance or strategic outlook was provided in this filing.
Industry Context
StockSavvy.ai notes that this filing is a standard regulatory disclosure for executive compensation and does not reflect a change in the company's strategic direction or market position.
Comparison to Industry Standards
- The practice of withholding shares to satisfy tax obligations upon RSU vesting is a standard industry practice for publicly traded companies in the biotechnology and healthcare sectors.
Stakeholder Impact
- Minimal impact on shareholders as the transaction is a standard tax-related share withholding.
Next Steps
- No future actions or milestones were disclosed in this filing.
Key Dates
| Date | Description |
|---|---|
| 02/26/2024 | Original grant date of restricted stock units. |
| 05/26/2026 | Date of the reported transaction involving share withholding. |
| 05/27/2026 | Date of filing for the Form 4. |
Keywords
Fulgent Genetics, FLGT, Insider Trading, Form 4, Ming Hsieh, Equity Compensation, Tax Withholding
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.